Durgical
EN
Open the app

How leukaemia is treated: induction, consolidation, targeted drugs and support

  • Treatment and support

Leukaemia treatment follows a logic: clear the marrow, hunt the last hidden cells, and keep the patient alive while the marrow recovers.

Updated

What it is

Acute leukaemia is treated in phases. Induction aims for complete remission (normal counts and fewer than 5% blasts in the marrow); consolidation, or intensification, removes the leukaemia that remains below what the microscope can see; in ALL a long maintenance phase follows and the brain is treated to prevent relapse. Targeted drugs aimed at a specific genetic lesion have changed CML, APL, Philadelphia-positive ALL and CLL. Allogeneic stem cell transplantation is used when relapse risk is high. Supportive care makes all of it possible.

What to know

  • AML in fit patients: intensive induction with cytarabine and an anthracycline, then consolidation chemotherapy or allogeneic transplant, chosen by genetic risk.
  • AML in older or less fit patients: lower-intensity therapy such as a hypomethylating agent with venetoclax; targeted drugs for FLT3 or IDH mutations.
  • APL: all-trans retinoic acid with arsenic trioxide cures most patients without conventional chemotherapy in lower-risk disease; differentiation syndrome is its key toxicity.
  • ALL: multi-drug induction (steroid, vincristine, asparaginase, often an anthracycline), CNS-directed therapy with intrathecal chemotherapy, then maintenance for about two to three years.
  • Targeted and immune therapy: tyrosine kinase inhibitors for CML and Philadelphia-positive ALL; blinatumomab and CAR-T cells for B-ALL; BTK inhibitors and venetoclax for CLL.
  • MRD measured by flow cytometry or molecular tests after induction is one of the strongest predictors of relapse and guides how intensive the rest of treatment is.
  • In Colombia, Ley 1388 de 2010 sets the right of children with suspected or confirmed cancer to prompt, comprehensive care.

How it is done (and why)

  1. Classify fully before treatment: marrow morphology, flow cytometry, cytogenetics and molecular tests define the type and risk.
  2. Prepare: fluids and uric acid control against tumour lysis, echocardiogram before anthracyclines, a central line, fertility discussion, infection screening.
  3. Induction: intensive treatment to empty the marrow of blasts, followed by weeks of profound neutropenia supported by transfusion and infection care.
  4. Assess remission and MRD on the marrow when counts recover.
  5. Consolidation: further chemotherapy, targeted drugs or allogeneic transplant to remove residual disease, the choice set by genetics and MRD.
  6. ALL only: CNS-directed treatment and long oral maintenance, because the brain and testes shelter blasts.
  7. Follow up: counts and MRD for relapse, and long-term effects (heart, fertility, growth in children, second cancers).

The phases and what each is for

PhaseGoalExampleMain risk
InductionComplete remissionCytarabine plus an anthracycline (AML); multi-drug induction (ALL)Weeks of neutropenia, infection, bleeding, tumour lysis
ConsolidationRemove residual diseaseFurther cycles, targeted drugs, or allogeneic transplantInfection, organ toxicity, graft-versus-host disease
Maintenance (ALL)Keep remaining cells suppressedOral antimetabolites for about two to three yearsLiver toxicity, low counts
CNS-directed (ALL)Treat blasts hidden in the brainIntrathecal chemotherapyNeurotoxicity
Targeted therapyHit the driver lesionTKIs (CML, Ph+ ALL); ATRA and arsenic (APL)Drug-specific: differentiation syndrome, QT prolongation

Risks and precautions

  • Vincristine given into the spinal fluid is fatal: it is only ever given intravenously, and intrathecal drugs are prepared and checked separately.
  • Asparaginase can cause pancreatitis, thrombosis (including cerebral venous thrombosis), low fibrinogen, liver injury and allergic reactions.
  • Anthracyclines damage the heart in a cumulative way, so heart function is checked before and during treatment and in survivors.
  • Differentiation syndrome with ATRA or arsenic: fever, breathlessness, lung infiltrates, weight gain and kidney injury; it is treated with steroids without delay.
  • Patients treated with purine analogues or undergoing transplant need irradiated blood components to prevent transfusion-associated graft-versus-host disease.

Monitoring and next step

  • Before treatment: full classification of the leukaemia, HLA typing of patient and siblings if transplant is possible, hepatitis B, HIV, echocardiogram.
  • During induction: daily count, electrolytes and tumour lysis panel early; coagulation and fibrinogen in APL and with asparaginase.
  • After induction and at set points: marrow for remission and MRD; BCR::ABL1 or PML::RARA levels when present.
  • Fever at any time during treatment: manage as febrile neutropenia within the first hour.

Common traps

  • Thinking remission means cure: without consolidation most AML relapses from cells the microscope cannot see.
  • Giving vincristine intrathecally: it is a never event that is almost always fatal.
  • Delaying ATRA in suspected APL while waiting for genetics: early bleeding deaths are the main threat.
  • Attributing fever and infiltrates in APL only to infection: it misses differentiation syndrome.
  • Forgetting irradiated blood after purine analogues or transplant: these patients need it.

Test yourself

Think of the answer, then tap the question to see it.

A patient with AML is in complete remission after induction. Why is more treatment still needed?

Remission only means blasts are below what the microscope can see; residual cells remain and cause relapse unless consolidation chemotherapy or a transplant removes them.

Why does ALL treatment include therapy aimed at the brain, while most AML treatment does not routinely?

Lymphoblasts frequently hide in the central nervous system, behind the blood-brain barrier, and relapse there unless intrathecal or CNS-penetrating therapy is given.

What does a positive MRD test after induction tell the team?

Leukaemia cells remain at a level below microscopic detection; relapse risk is high, so treatment is usually intensified, for example towards transplant or immunotherapy.

A patient with APL on ATRA develops fever, breathlessness, infiltrates and weight gain. What is it, and what is done?

Differentiation syndrome; steroids are started at once and the team weighs pausing the drug, while infection is also excluded.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Childhood Acute Lymphoblastic Leukemia (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Stem Cell Transplants in Cancer Treatment (National Cancer Institute, 2024); Control integral del cáncer infantil en Colombia: aspectos políticos y normativos (Ley 1388 de 2010) (Ministerio de Salud y Protección Social de Colombia, 2015).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.